Although further molecular biological analysis is required to investigate the usefulness of candidate genes other than KRAS and BRAF, assessing KRAS mutation could be a very useful tool for treating sporadic nonampullary duodenal adenocarcinoma. Here, BRAF is linked to duodenal adenocarcinoma.